What this means
This is a trial registration, not a result. It says researchers plan to compare how well and how safely these drugs work in older and younger women. It does not yet show whether they work better or worse for older women.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18 and over
- Where
- 1 site
The science
- Registered title
- CDK4/6 Inhibitors in Breast Cancer Elderly Patients: an Observational Ambispective Longitudinal Multicenter Study
- Trial ID
- NCT07399808 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- Breast Cancer, Old Age
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Ages
- 18 Years to no maximum
- Dates
- First posted Feb 10, 2026 · updated Feb 10, 2026
Registry summary
Breast cancer is one of the tumors with the highest incidence and current evidence indicates a higher prevalence in elderly patients (≥70 years) with a higher mortality rate due to immunosenescence, diagnostic delay and under treatment. Elderly patients are still poorly represented in clinical trials and the main indications for the treatment of the elderly population are extrapolated from the guidelines used in studies conducted predominantly on the younger population. In particular, these guidelines do not take into account the significant variability of elderly patients, in particular their comorbidities, performance status, physiological age and frailty.
The aim of this study is to improve understanding of the clinical efficacy and safety of CDK 4/6i in older women in a real-world setting compared to younger women.
Sites (1)
- Fondazione IRCCS Policlinico San Matteo di Pavia, Pavia, Pavia, Italy